Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Ferrari

Surgery Fort Smith, AR Medical Doctor

NPI 1417264250 CMS profile 1001472

2713 S 74Th St Ste 401, Fort Smith, AR 72903

Open in the dashboard

General payments

$20,404

76 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Ferrari of Fort Smith, AR is reported in the CMS Open Payments database as having received $20,404 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,385 8
2024 General $2,137 21
2023 General $1,574 11
2022 General $2,538 13
2021 General $11,471 11
2020 General $972 3
2019 General $327 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Ferrari
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Jonathan Ferrari were reported at $1,385. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Jonathan Ferrari Surgery median Middle half National median
2019 $327 $253 $82–$1,521 $163
2020 $972 $131 $40–$706 $114
2021 $11,471 $168 $50–$904 $132
2022 $2,538 $224 $76–$1,218 $149
2023 $1,574 $253 $82–$1,255 $160
2024 $2,137 $279 $90–$1,381 $164
2025 $1,385 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $18,703 40 payments
  2. Medtronic, Inc. $993 7 payments
  3. Enterra Medical, Inc. $121 1 payment
  4. PolyNovo North America LLC $58 2 payments
  5. Smith+Nephew, Inc. $38 2 payments
  6. AbbVie, Inc. $35 2 payments
  7. Innovation Technologies Inc $33 1 payment
  8. Ethicon US, LLC $32 1 payment
  9. Organogenesis Inc. $31 1 payment
  10. W. L. Gore & Associates, Inc. $30 1 payment
  11. Other $328 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $11,133 6 payments
  2. Travel and Lodging $6,643 24 payments
  3. Food and Beverage $2,586 44 payments
  4. Gift $43 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System Surgery $11,000 4 payments
  2. Da Vinci Surgical System Surgery $7,703 36 payments
  3. LigaSure $993 7 payments
  4. DALVANCE $58 4 payments
  5. STRAVIX $38 2 payments
  6. Irrisept $33 1 payment
  7. EVICEL Fibrin Sealant (Human) $32 1 payment
  8. Puraply $31 1 payment
  9. GORE ENFORM Preperitoneal Biomaterial $30 1 payment
  10. No Related Product $30 1 payment
  11. Other $350 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

274

Median for General Surgery: 59

Drug cost

$1,225

Median for General Surgery: $393

Branded share of claims

56.2%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 113 $654
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 41 $163
Neomycin Sulfate Generic 18 $97
Omeprazole Generic 11 $95
Pantoprazole Sodium Generic 12 $95
Ondansetron Hcl Generic 43 $69
Metronidazole Generic 19 $33
Ibuprofen Generic 17 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$76,059

Medicare's payments for the services billed

Medicare patients

201

Average age 71

Services billed

367

106 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 38%
Ischemic heart disease 35%
Chronic kidney disease 35%
Depression 31%
Heart failure 26%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record